Diagnostic and prognostic values of upregulated SPC25 in patients with hepatocellular carcinoma

Xiaolin Yang1*, Hongzhi Sun2*, Ying Song3, Li Yang4 and Haibo Liu5

1 Department of Geriatrics, the First Hospital of Jilin University, Changchun, China
2 Department of Emergency and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, China
3 Department of Gastroenterology, The Second Hospital of Jilin University, Changchun, China
4 Department of Gastroenterology, First Automobile Works General Hospital of Jilin Province, Changchun, China
5 Department of Emergency, The First Hospital of Jilin University, Changchun, China

* These authors contributed equally to this work.

ABSTRACT

Background. Spindle pole body component 25 (SPC25) plays a vital role in many cellular processes, such as tumorigenesis. However, the clinical significance of SPC25 in hepatocellular carcinoma (HCC) has not been investigated. This study aimed to explore the expression patterns of SPC25 in HCC and non-neoplastic tissues and to investigate the diagnostic and prognostic values of SPC25.

Method. The expression of SPC25 was examined in 374 HCC issues and 50 non-neoplastic tissues from The Cancer Genome Atlas (TCGA) cohort. The diagnostic and prognostic values of SPC25 were analyzed via receiver operating characteristic (ROC) curve and survival analyses, respectively. Univariate and multivariate Cox regression analyses were used to identify the prognostic factors and to establish a nomogram. The diagnostic and prognostic values were further validated in an external cohort from the International Cancer Genome Consortium (ICGC) database.

Results. The expression of SPC25 in HCC tissues was significantly higher than that in normal tissues in both cohorts (all \( P < 0.001 \)). The ROC curve analysis indicated that SPC25 expression has high diagnostic value in HCC with area under the curve (AUC) value of 0.969 (95% confidence interval [CI] [0.948–0.984]) and 0.945 (95% CI [0.920–0.965]) for TCGA and ICGC cohorts, respectively. Patients with HCC exhibiting high SPC25 expression were associated with worse prognosis than those exhibiting low SPC25 expression in both cohorts (all \( P < 0.001 \)). SPC25 was independently associated with overall survival in both cohorts (all \( P < 0.001 \)). The concordance indices of the nomogram for predicting overall survival in TCGA and ICGC cohorts were 0.647 and 0.805, respectively, which were higher than those of the American Joint Committee on Cancer (AJCC) staging system.

Conclusion. SPC25 was upregulated in HCC and independently predicted poor overall survival of patients with HCC. Therefore, SPC25 is an effective diagnostic and prognostic biomarker for HCC. An SPC25-based nomogram was more accurate and useful than the AJCC staging system to predict prognosis of HCC.
INTRODUCTION

Hepatocellular carcinoma (HCC) is the predominant cancer type among the primary liver cancers. Among the malignant tumors, HCC is the sixth most common cancer and is associated with fourth highest cancer-related mortality (Bray et al., 2018). In 2008, approximately 840,000 new cases of HCC were recorded globally, which resulted in approximately 780,000 deaths (Bray et al., 2018). In China, more than 466,100 new HCC cases and 422,100 HCC-related deaths were reported in 2015 (Chen et al., 2016). Nowadays, rapid advances has been made in the therapy of HCC thanks to the encouraging progress in early diagnosis and cancer therapeutic methods such as imaging techniques, liver transplantation, surgical resection, local ablation, and transcatheter arterial chemoembolization and comprehensive therapy (Zhang et al., 2018). However, the 5-year survival rate of patients with HCC remains low due to the high rates of local recurrence and distant metastasis (Allemani et al., 2015). Several studies have demonstrated that various aberrantly expressed genes can be used to determine HCC prognosis (Chen et al., 2018b; Feng et al., 2019; Yu et al., 2019; Zhu et al., 2019). For example, low expression of CTC-297N7.9 is associated with poor prognosis in HCC patients, and could be used as an independent prognostic indicator in HCC patients. However, its diagnostic capability is limited in discriminating HCC tissues from normal tissues with an AUC of 0.74 (Zhu et al., 2019). The knockdown of TMEM16A inhibited HCC cell proliferation, migration and induced cell apoptosis, and upregulation of TMEM16A induced HCC cell growth, migration and reduced cell apoptosis (Zhang et al., 2020). However, its diagnostic capability in discriminating HCC tissues from normal tissues was unknown. Currently, serum alpha-fetoprotein is the most reliable HCC biomarker although it has low sensitivity and specificity in the diagnosis of HCC (Chaiteerakij, Addissie & Roberts, 2015; Daniele et al., 2004). Therefore, there is an urgent need to identify and validate novel reliable diagnostic and prognostic biomarkers for HCC.

Spindle pole body component 25 (SPC25), a component of the nuclear division cycle 80 (Ndc80) complex, is involved in kinetochore-microtubule interactions and spindle checkpoint activity (McCleland et al., 2004; Tooley & Stukenberg, 2011). Previous studies have reported that dysregulated SPC25 expression is associated with the oncogenic process and malignant phenotypes of several cancers. The upregulated expression of SPC25 has been reported in colorectal, gastric cancers, breast, and lung adenocarcinoma. Additionally, SPC25 is involved in carcinogenesis, cancer cell growth, and metastasis (Chen et al., 2018a; Jeong et al., 2018; Kaneko et al., 2009; Wang et al., 2019). A cell-based assay revealed that the SPC25 can be a potential biomarker for Alzheimer’s disease as the expression level of SPC25 was significantly upregulated in the serum samples of patients with mild cognitive impairment (Zhang et al., 2018). In the HCC cells, PRC1 regulates the expression and function of recurrence-associated genes, such as SPC25, KIF11 FANCI, and KIF23 via...
Wnt signalling (Zhu et al., 2019). However, the correlation between SPC25 expression and HCC for diagnosis and prognosis of HCC has not been previously evaluated. This study aimed to analyze the SPC25 mRNA expression patterns and to determine the diagnostic and prognostic values of SPC25 expression in HCC.

In this study, we evaluated the mRNA expression of SPC25 in patients with HCC based on the data obtained from The Cancer Genome Atlas (TCGA) database. Additionally, the correlation between SPC25 expression and clinicopathological features, as well as the potential diagnostic and prognostic values of SPC25 in patients with HCC were analyzed. Furthermore, TCGA analysis results were validated using an external cohort from the International Cancer Genome Consortium (ICGC) database. A nomogram prognostic model based on SPC25 was constructed. The accuracy of the prognostic model was compared with that of the currently used American Joint Committee on Cancer (AJCC) staging system in both cohorts.

**MATERIAL AND METHODS**

**SPC25 expression data and clinicopathological characteristics**

The gene expression profiles of 374 human HCC tissues and 50 non-neoplastic tissues, as well as the clinical data of patients, such as age at diagnosis, sex, histologic grade, pathological stage, vascular invasion, family history of cancer, survival status, and survival time were downloaded from TCGA Liver Hepatocellular Carcinoma (TCGA-LIHC; https://portal.gdc.cancer.gov/) database. The mRNA expression levels of SPC25 in TCGA cohort were extracted. The expression levels of SPC25 in HCC and non-tumorous tissues were comparatively analyzed in R (version 3.6.3) using the limma package (Ritchie et al., 2015). Next, the expression data and clinical data were merged using the patients’ unique identification numbers. In total, 370 patients were included in the final analysis. The relationship between SPC25 expression and clinical parameters was analyzed in these patients. The patients were classified into high expression and low expression groups based on the median SPC25 expression level in patients with HCC. The differences in the overall survival rates between the two groups were analyzed using R (version 3.6.3) ‘survival’ package (https://CRAN.R-project.org/package=survival). Furthermore, ESTIMATE (Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data) algorithm was used to estimate the tumor purity, and the presence of infiltrating stromal/immune cells in tumor microenvironment for each sample. We analyzed the relationships between SPC25 expression and immune cell infiltration (Yoshihara et al., 2013).

**Statistical analysis**

The correlation between SPC25 expression and clinicopathological characteristics was evaluated using the Chi-square test and logistic regression and was represented with box plots. The area under the curve (AUC) value obtained from the receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic effectiveness of SPC25 in discriminating HCC tissues from normal tissues in both cohorts using the pROC package (Robin et al., 2011). An AUC value greater than 0.85 is considered to have
outstanding predictive value (Metz, 1978). Kaplan–Meier curves with P-value calculated by the log-rank test were used to compare the differences in overall survival rates. The univariate Cox regression analysis was performed to identify the possible prognostic variables. The multivariate Cox analysis was performed to verify the effect of SPC25 expression level on prognosis along with other clinical factors. The variables with \( P < 0.05 \) in the univariate analysis were adjusted in the multivariate analysis. A nomogram was established based on the independent clinicopathological factors in TCGA cohort using the ‘rms’ package (https://CRAN.R-project.org/package=rms). The nomogram was validated by analyzing discrimination and calibration curves in both cohorts. The concordance index (C-index) was used to evaluate the discrimination of the nomogram. The decision curve analysis (DCA, https://CRAN.R-project.org/package=rmda) was performed to test the clinical utility of the model between the SPC25-based nomogram, the AJCC staging system, and alpha-fetoprotein levels. The differences were considered statistically significant when the \( P \)-value was less than 0.05. All statistical analyses were performed using the R software (V.3.6.3, http://www.r-project.org).

Validation of the diagnostic and prognostic values of SPC25 using an external database

To obtain reliable results, the mRNA expression profiles of 240 HCC cases and 260 adjacent nontumor tissues with clinical data downloaded from the ICGC database (https://dcc.icgc.org/projects/LIRI-JP) were analyzed following the same methodology used to analyze TCGA cohort. Among the ICGC cohort, 202 adjacent nontumor tissues from patients with cancer and 240 primary tumor samples from patients with HCC were included in this study to validate the results of TCGA cohort analysis.

RESULTS

SPC25 expression in patients with varied clinicopathological parameters

The correlation between SPC25 expression and clinicopathological characteristics in patients with HCC was represented using the box plots. The clinical data of patients in the internal validation group and the external validation group were shown in Table 1. As shown in Fig. 1, high SPC25 expression was associated with patient age \((P = 0.025, \text{Fig. } 1A)\), pathological stage \((P = 0.004, \text{Fig. } 1C)\), histologic grade \((P < 0.0001, \text{Fig. } 1D)\), survival status \((P = 0.00029, \text{Fig. } 1E)\), and family history of cancer \((P = 0.01, \text{Fig. } 1G)\). However, SPC25 expression was not significantly correlated with sex and vascular invasion (all \( P > 0.05 \), Figs. 1B and 1F). The differences in the SPC25 expression level in HCC tissues and non-tumorous tissues were represented using a boxplot. The expression level of SPC25 in HCC tissues was significantly upregulated when compared with that in normal tissues (Fig. 2A, \( P < 0.0001 \)). Next, the expression level of SPC25 in 50 paired HCC tissues and non-neoplastic tissues from TCGA cohort was analyzed. The expression level of SPC25 in HCC tissues was upregulated when compared with that in non-neoplastic tissues (Fig. 2B, \( P < 0.0001 \)).
Table 1  Clinical data of patients in the internal validation group and the external validation group.

| Variables       | Subgroups | TCGA | ICGC |
|-----------------|-----------|------|------|
| Age             | <65       | 221  | 85   |
|                 | ≥65       | 149  | 155  |
| Sex             | Male      | 249  | 179  |
|                 | Female    | 121  | 61   |
| Stage           | I         | 171  | 36   |
|                 | II        | 85   | 109  |
|                 | III       | 85   | 74   |
|                 | IV        | 5    | 21   |
|                 | NA        | 24   | 0    |
| Grade           | I         | 55   | –    |
|                 | II        | 177  | –    |
|                 | III       | 121  | –    |
|                 | IV        | 12   | –    |
|                 | NA        | 5    | –    |
| Survival status | Dead      | 130  | 43   |
|                 | Living    | 240  | 197  |
| Vascular invasion | Positive | 108  | –    |
|                 | Negative  | 206  | –    |
|                 | NA        | 56   | –    |
| Family history  | Positive  | 112  | 76   |
|                 | Negative  | 207  | 149  |
|                 | NA        | 51   | 15   |
| Prior malignancy| Positive  | –    | 32   |
|                 | Negative  | –    | 208  |
|                 | NA        | –    | 0    |

Logistic regression analysis revealed that upregulated SPC25 expression in HCC was closely associated with age (odds risk [OR] = 0.568 for ≥65 vs <65, 95% CI [0.372–0.863], P = 0.0083), pathological stage (OR = 1.957 for stage III + stage IV vs stage I + stage II, 95% CI [1.202–3.223], P = 0.0075), histologic grade (OR= 4.936 for grade 3 vs grade 1, 95% CI [2.506–10.104], P < 0.001; OR= 12.187 for grade 4 vs grade 1, 95% CI [2.827–85.344], P = 0.0026), and patients survival status (OR = 1.958 for dead vs. alive, 95% CI [1.272–3.036], P = 0.0024) (Table 2).
Figure 1  SPC25 mRNA expression varied significantly in patients with hepatocellular carcinoma (HCC) exhibiting different clinicopathological characteristics. The SPC25 expression level was compared between HCC samples and non-tumorous samples in from The Cancer Genome Atlas (TCGA) cohort according to (A) age, (B) gender, (C) pathological stage, (D) histologic grade, (E) survival status, (F) vascular invasion, and (G) family history of cancer.

Diagnostic and prognostic values of upregulated SPC25 expression in patients with HCC

The prognostic value of SPC25 in patients with HCC was evaluated. The Kaplan–Meier curve demonstrated that high SPC25 expression was significantly associated with unfavorable overall survival (Fig. 2C, \( P < 0.001 \)). To assess the diagnostic value of SPC25, we generated an ROC curve using the SPC25 expression data from 370 HCC tissues and 50 non-neoplastic tissues. As shown in Fig. 2D, SPC25 had an excellent diagnostic value in discriminating HCC tissues from normal tissues with an AUC of 0.969 (95% CI [0.94.8–0.984]), sensitivity of 92.78% (95% CI [89.7–95.2%]), and specificity of 94.00 (95% CI [83.5–98.7]%).

We further explored the expression level of SPC25 in other gastrointestinal tract malignances. As shown in Fig. 3, the expression levels of SPC25 in cholangiocarcinoma, colon adenocarcinoma, pancreatic adenocarcinoma, rectum adenocarcinoma, LIHC, and stomach adenocarcinoma were significantly higher than those in non-neoplastic tissues. To confirm the prognostic value of SPC25 expression, univariate and multivariate analyses were performed. The univariate analysis revealed that age, sex, pathological stage, and SPC25 expression were significantly correlated with overall survival (all \( P < 0.05 \)). After
adjusting for other prognostic variables, the multivariate analysis revealed that SPC25 expression was independently associated with overall survival (hazard ratio [HR] = 1.76, 95% CI [1.100–2.815], \( P = 0.0183 \)). All other independent risk variables, including age and pathological stage, and the corresponding HR and 95% CI are listed in Table 3.

**Nomogram construction and validation**

Based on the results from multivariate Cox analysis, age, pathological stage, and SPC25 expression were identified as independent prognostic factors for overall survival. Nomograms for predicting 1-, 3-, and 5-year overall survival rates were established based on these independent risk factors in TCGA cohort (Fig. 4A). The internal validation...
Table 2  Logistic regression of SPC25 expression associated with clinical pathological characteristics.

| Clinical characteristics                          | Total (N) | Odds ratio in SPC25 expression | 95% CI         | P-Value |
|--------------------------------------------------|-----------|--------------------------------|----------------|---------|
| Pathological stage (III + IV vs I + II)           | 346       | 1.957                          | 1.202–3.223    | 0.0075  |
| Histologic grade (G2 vs G1)                      | 232       | 1.792                          | 0.946–3.523    | 0.0802  |
| (G3 vs G1)                                       | 176       | 4.936                          | 2.506–10.104   | <0.0001 |
| (G4 vs G1)                                       | 67        | 12.187                         | 2.827–85.344   | 0.0026  |
| Age (≥65 vs <65)                                 | 370       | 0.568                          | 0.372–0.863    | 0.0083  |
| Gender (Male vs Female)                          | 370       | 0.621                          | 0.542–1.127    | 0.0854  |
| Survival status (Dead vs Alive)                  | 370       | 1.958                          | 1.272–3.036    | 0.0024  |
| Family history of cancer (Yes vs No)             | 319       | 0.686                          | 0.431–1.088    | 0.11    |
| Vascular invasion (Yes vs No)                    | 314       | 1.487                          | 0.932–2.383    | 0.0969  |

Notes.
*Statistically significant P-values are given in bold, P < 0.05.

Figure 3  The expression of SPC25 in colon adenocarcinoma, LIHC, pancreatic adenocarcinoma, stomach adenocarcinoma, rectum adenocarcinoma, cholangiocarcinoma, and corresponding non-tumorous tissues.

Full-size DOI: 10.7717/peerj.9535/fig-3

Table 3  Univariate and multivariate analysis of the relationship of SPC25 expression with overall survival among hepatocellular carcinoma patients.

| Variables                | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR                  | 95% CI                | P-value   | HR                  | HR.95 L       | P-value   |
| Age                      | 1.021               | 1.002–1.040           | 0.0267    | 1.02                | 1.001–1.040   | 0.0421    |
| Sex                      | 0.587               | 0.373–0.923           | 0.0211    | 0.796               | 0.490–1.294   | 0.358     |
| Stage                    | 1.465               | 1.142–1.879           | 0.0027    | 1.415               | 1.097–1.824   | 0.0075    |
| SPC25                    | 1.776               | 1.121–2.814           | 0.0144    | 1.76                | 1.100–2.815   | 0.0183    |
| Grade                    | 1.221               | 0.893–1.669           | 0.2116    |                     |                |           |
| Vascular invasion        | 1.443               | 0.904–2.305           | 0.1244    |                     |                |           |
| Family history of cancer | 1.418               | 0.903–2.225           | 0.1291    |                     |                |           |

Notes.
SPC25, spindle pole body component 25; HR, hazard ratio; CI, confidence interval.
Bold values indicate P < 0.05.
### Figure 4  Nomogram for overall survival, calibration plots of the nomogram, and decision curve analysis of nomogram and American Joint Committee on Cancer (AJCC) staging system.

(A) The nomogram predicted 1-, 3-, and 5-year overall survival rates of patients with hepatocellular carcinoma in The Cancer Genome Atlas (TCGA) cohort. (B) The calibration curves predict 1-, 3-, and 5-year overall survival rates in TCGA cohort. (C) The calibration curves predicting the 1- and 3-year overall survival in the International Cancer Genome Consortium cohort. (D) The predicted survival rates in TCGA cohort by nomogram and AJCC staging system were comparatively analyzed. (E) The predicted survival rates in the International Cancer Genome Consortium cohort by nomogram and AJCC staging system were comparatively analyzed.

Full-size DOI: 10.7717/peerj.9535/fig-4

In TCGA cohort demonstrated that the C-index of nomogram for overall survival was 0.647 (95% CI [0.582–0.711]), which was higher than that of the AJCC staging (C-index = 0.558; 95% CI [0.494–0.622]) and alpha-fetoprotein levels (C-index = 0.425, 95% CI [0.350–0.501]). In the ICGC cohort, the C-index for nomogram to predict overall survival was 0.805 (95% CI [0.745–0.864]), which was higher than that of AJCC staging (C-index = 0.705, 95% CI [0.634–0.780]). The calibration plots in TCGA cohort (Fig. 4B) and ICGC cohort (Fig. 4C) demonstrated an excellent agreement between the nomogram prediction and observed estimates for 1-, 3-, and 5-year overall survival rates. In the DCA analysis, the nomogram presented preferable net benefit with a wider range of threshold probabilities when compared with the AJCC stage system and alpha-fetoprotein levels in both cohorts (Figs. 4D and 4E). These results suggest that the SPC25-based nomogram is superior to the AJCC stage system in predicting HCC prognosis.
Validation of the diagnostic and prognostic values of SPC25 in the ICGC cohort

External validation further confirmed that the expression of SPC25 in HCC tissues was higher than that in adjacent tissues (Fig. 5A, \( P < 0.0001 \)). The Kaplan-Meir analysis revealed that the high SPC25 expression group had an unfavorable prognosis when compared with the low SPC25 expression group (Fig. 5B, \( P < 0.001 \)). The diagnostic value of SPC25 also demonstrated excellent performance in the ICGC cohort with an AUC of 0.945 (95% CI [0.920–0.965], Fig. 5C). The univariate analysis indicated that SPC25 expression, sex, and pathological stage were correlated with overall survival (all \( P < 0.005 \), Fig. 5D). After adjusting for other risk factors, the multivariate analysis results confirmed that SPC25 expression was independently correlated with survival in patients with HCC (HR = 6.495, 95% CI [2.646–15.946], \( P < 0.001 \), Fig. 5E). These results indicate that SPC25 is a novel diagnostic and prognostic biomarker for HCC.

Correlation of SPC25 with the proportion of tumor-infiltrating immune cells

Furthermore, the correlation of SPC25 expression with the immune microenvironment was explored among 21 kinds of immune cell profiles in LIHC samples. The results from the correlation analyses demonstrated that a total of 3 kinds of tumor-infiltrating immune cells were correlated with the expression of SPC25 (Fig. 6). Among them, activated CD4 T memory cells were positively correlated with SPC25 expression (Fig. 6A); two kinds of tumor-infiltrating immune cells were negatively correlated with SPC25 expression, including regulatory T cells (Tregs), and resting memory CD4+ T cells (Figs. 6B–6C). These results further indicated that the levels of SPC25 affected the immune activity of immune microenvironment to a certain extent.

DISCUSSION

In this study, the expression of SPC25 in HCC tissues was upregulated when compared with that in normal tissues. The expression of SPC25 was related to age, pathological stage, histologic grade, survival status, and family history of cancer. The Kaplan–Meier analysis of overall survival revealed that high expression of SPC25 was associated with unfavorable prognosis in patients with HCC. The ROC analysis confirmed that SPC25 had an excellent diagnostic value in discriminating HCC tissues from normal tissues. The univariate and multivariate analyses revealed that upregulated SPC25 expression was an independent prognostic factor of short overall survival. These results were successfully validated in an external (ICGC) cohort. These findings suggest that SPC25 expression can serve as a promising biomarker of poor prognosis in patients with HCC.

SPC25, a key component of the Ndc80 complex, can form a heterodimer with SPC24 to regulate microtubule-kinetochore attachment, chromosome alignment, and spindle checkpoint activation during mitosis process (McCleland et al., 2004; Sun et al., 2010). Recent studies have reported that the aberrant expression of Ndc80 complex is involved in the progression of human cancer (Fu & Shao, 2016; Hu et al., 2015). Tumorigenesis can result from genetic instability in the cell cycle, which is caused due to defects in
Figure 5  The validation of the expression levels and diagnostic and prognostic values of SPC25 in hepatocellular carcinoma in the International Cancer Genome Consortium cohort. (A) The expression level of SPC25 in hepatocellular carcinoma was upregulated when compared with that in normal solid tissues ($P < 0.0001$). (B) High SPC25 expression was associated with an unfavorable overall survival in patients with hepatocellular carcinoma ($P < 0.0001$). (C) Diagnosis value of SPC25 expression in hepatocellular carcinoma in the International Cancer Genome Consortium cohort. (D) Univariate analysis and (E) multivariate analysis of the correlation of SPC25 expression with overall survival among patients with hepatocellular carcinoma.

Full-size DOI: 10.7717/peerj.9535/fig-5

As the expression of SPC25 plays an important role in overall survival in patients with HCC, we determined whether it can be used to develop an improved prognostic model.
CONCLUSION

This study, for the first time, demonstrated that SPC25 expression, which was upregulated in HCC tissues, was correlated with an unfavorable prognosis in patients with HCC using TCGA and ICGC cohorts. SPC25 expression may be a powerful diagnostic and prognostic
biomarker for HCC. An SPC25-based nomogram was more accurate and useful than the AJCC staging system.

**ACKNOWLEDGEMENTS**

The authors thank the efforts of the TCGA (https://portal.gdc.cancer.gov/repository) database, and the International Cancer Genome Consortium (https://dcc.icgc.org/) database in the creation of the databases.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**

The authors received no funding for this work.

**Competing Interests**

The authors declare there are no competing interests.

**Author Contributions**

- Xiaolin Yang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Hongzhi Sun performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Ying Song conceived and designed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Li Yang conceived and designed the experiments, prepared figures and/or tables, and approved the final draft.
- Haibo Liu conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

**Data Availability**

The following information was supplied regarding data availability:

Data are available at TCGA (search terms: SPC25 and TCGA-LIHC) and at the ICGC Data Portal (search terms: LIHC-JP; https://dcc.icgc.org/).

**REFERENCES**

Allemanni C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeborg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP. 2015. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* **385**:977–1010 DOI 10.1016/s0140-6736(14)62038-9.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68:394–424 DOI 10.3322/caac.21492.

Chaiteerakij R, Addissie BD, Roberts LR. 2015. Update on biomarkers of hepatocellular carcinoma. Clinical Gastroenterology and Hepatology 13:237–245 DOI 10.1016/j.cgh.2013.10.038.

Charlton ME, Adamo MP, Sun L, Deorah S. 2014. Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004–2010. Cancer 120(Suppl 23):3815–3825 DOI 10.1002/cncr.29047.

Chen J, Chen H, Yang H, Dai H. 2018a. SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival. Biomedicine and Pharmacotherapy 100:233–239 DOI 10.1016/j.biopharma.2018.02.015.

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. 2016. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians 66:115–132 DOI 10.3322/caac.21338.

Chen Y, Zhao J, Jiao Z, Wang W, Wang D, Yu X, Shi Z, Ge N, Pan Q, Xia J, Niu W, Zhao R, Zhang X, Du W. 2018b. SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma. BMC Cancer 18:1240 DOI 10.1186/s12885-018-5119-6.

Cui F, Hu J, Fan Y, Tan J, Tang H. 2018. Knockdown of spindle pole body component 25 homolog inhibits cell proliferation and cycle progression in prostate cancer. Oncology Letters 15:5712–5720 DOI 10.3892/ol.2018.8003.

Daniele B, Bencivenga A, Megna AS, Tinessa V. 2004. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127:S108–S112 DOI 10.1053/j.gastro.2004.09.023.

Feng H, Fang F, Yuan L, Xiao M, Yang XY, Huang Y. 2019. Downregulated expression of CFHL1 is associated with unfavorable prognosis in postoperative patients with hepatocellular carcinoma. Experimental and Therapeutic Medicine 17:4073–4079 DOI 10.3892/etm.2019.7455.

Fu HL, Shao L. 2016. Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells. European Review for Medical and Pharmacological Sciences 20:1071–1079.

Hu P, Chen X, Sun J, Bie P, Zhang LD. 2015. siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Bioscience Reports 35(1):e00170 DOI 10.1042/bsr20140124.

Jeong J, Keum S, Kim D, You E, Ko P, Lee J, Kim J, Kim JW, Rhee S. 2018. Spindle pole body component 25 homolog expressed by ECM stiffening is required for lung cancer cell proliferation. Biochemical and Biophysical Research Communications 500:937–943 DOI 10.1016/j.bbrc.2018.04.205.

Kaneko N, Miura K, Gu Z, Karasawa H, Ohnuma S, Sasaki H, Tsukamoto N, Yokoyama S, Yamamura A, Nagase H, Shibata C, Sasaki I, Hori A. 2009. siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in
colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis. *Biochemical and Biophysical Research Communications* **390**:1235–1240 DOI 10.1016/j.bbrc.2009.10.127.

McCleland ML, Kallio MJ, Barrett-Wilt GA, Kestner CA, Shabanowitz J, Hunt DF, Gorbsky GJ, Stukenberg PT. 2004. The vertebrate Ndc80 complex contains Spc24 and Spc25 homologs, which are required to establish and maintain kinetochore-microtubule attachment. *Current Biology* **14**:131–137 DOI 10.1016/j.cub.2003.12.058.

Metz CE. 1978. Basic principles of ROC analysis. *Seminars in Nuclear Medicine* **8**:283–298 DOI 10.1016/s0001-2998(78)80014-2.

Pathania R, Ramachandran S, Mariappan G, Thakur P, Shi H, Choi JH, Manicassamy S, Kolhe R, Prasad PD, Sharma S, Lokeshwar BL, Ganapathy V, Thangaraju M. 2016. Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. *Cancer Research* **76**:3224–3235 DOI 10.1158/0008-5472.can-15-2249.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* **43**:e47 DOI 10.1093/nar/gkv007.

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. 2011. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* **12**:77 DOI 10.1186/1471-2105-12-77.

Sun SC, Lee SE, Xu YN, Kim NH. 2010. Perturbation of Spc25 expression affects meiotic spindle organization, chromosome alignment and spindle assembly checkpoint in mouse oocytes. *Cell Cycle* **9**:4552–4559 DOI 10.4161/cc.9.22.13815.

Tooley J, Stukenberg PT. 2011. The Ndc80 complex: integrating the kinetochore’s many movements. *Chromosome Research* **19**:377–391 DOI 10.1007/s10577-010-9180-5.

Wang Q, Zhu Y, Li Z, Bu Q, Sun T, Wang H, Sun H, Cao X. 2019. Up-regulation of SPC25 promotes breast cancer. *Aging* **11**:5689–5704 DOI 10.18632/aging.102153.

Xiao Z, Yan Y, Zhou Q, Liu H, Huang P, Zhou Q, Lai C, Zhang J, Wang J, Mao K. 2019. Development and external validation of prognostic nomograms in hepatocellular carcinoma patients: a population based study. *Cancer Management and Research* **11**:2691–2708 DOI 10.2147/cmar.s191287.

Yu S, Li X, Guo X, Zhang H, Qin R, Wang M. 2019. UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma. *IUBMB Life* **71**:105–112 DOI 10.1002/iub.1941.
Zhang C, Liu J, Han Z, Cui X, Peng D, Xing Y. 2020. Inhibition of TMEM16A suppresses growth and induces apoptosis in hepatocellular carcinoma. *Int J Clin Oncol* 25:1145–1154 DOI 10.1007/s10147-020-01653-6.

Zhang X, Li J, Shen F, Lau WY. 2018. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology* 33:347–354 DOI 10.1111/jgh.13843.

Zhu S, Huang X, Zhang K, Tan W, Lin Z, He Q, Chen Y, Shang C. 2019. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma. *Cancer Medicine* 8:7679–7692 DOI 10.1002/cam4.2618.